Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact
Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact
Enovis Corporation's (NYSE:ENOV) fourth-quarter net sales reached $455 million, up 11% Y/Y, including 8% organic growth, beating the consensus of $445.36 million.
伊诺维斯公司（纽约证券交易所代码：ENOV）第四季度的净销售额达到4.55亿美元，同比增长11％，包括8％的有机增长，超过了预期的4.4536亿美元。
Fourth quarter results reflect continued execution in P&R, above-market growth in Recon, and the impact of recent acquisitions.
第四季度的业绩反映了P&R的持续执行、Recon高于市场的增长以及最近收购的影响。
Compared to the same quarter in 2022, net sales in Recon grew 18%, with 11% organic sales growth, and P&R grew 8%, with 6% organic sales growth.
与2022年同期相比，Recon的净销售额增长了18％，有机销售增长了11％，P＆R增长了8％，有机销售增长了6％。
Also Read: This Analyst Sees Durable Share Gains, Margin Expansion For Orthopedics-Focused Enovis.
另请阅读：这位分析师认为，专注于骨科的Enovis的份额将持续上涨，利润率扩大。
Enovis reported a fourth-quarter net income from continuing operations of $3 million and an adjusted EBITDA of $82 million, or 18% of sales, a decline of 30 basis points versus the comparable prior year quarter, which includes the temporary dilution of recent acquisitions.
Enovis报告称，第四季度来自持续经营业务的净收入为300万美元，调整后的息税折旧摊销前利润为8200万美元，占销售额的18％，与去年同期相比下降了30个基点，其中包括对近期收购的暂时稀释。
The company reported adjusted earnings per diluted share of $0.79, beating the consensus of $0.74.
该公司报告调整后的摊薄后每股收益为0.79美元，超过市场预期的0.74美元。
"We are very pleased with our results in 2023, with both revenues and operating margins exceeding expectations while continuing to make investments in key growth initiatives and M&A," said Matt Trerotola, Chief Executive Officer of Enovis. "We look forward to carrying this momentum into 2024, which is setting up to be a transformative year as we integrate Lima and kick off a multi-year cadence of new product introductions across Recon and P&R."
Enovis首席执行官马特·特雷罗托拉表示：“我们对2023年的业绩感到非常满意，收入和营业利润率均超出预期，同时继续投资关键增长计划和并购。”“我们期待将这一势头延续到2024年，这将是变革性的一年，因为我们将整合利马，并在Recon和P＆R开始了为期多年的新产品推出。”
Guidance: Enovis forecasts fiscal year 2024 revenue of approximately $2.05 billion-$2.15 billion versus a consensus of $2.12 billion.
指导：Enovis预测2024财年的收入约为20.5亿美元至21.5亿美元，而市场普遍预期为21.2亿美元。
The guidance includes $290 million-$300 million of revenue related to the Lima acquisition, which closed on January 3, 2024.
该指导方针包括与利马收购相关的2.9亿至3亿美元的收入，该收购于2024年1月3日完成。
It guided for an adjusted EBITDA of $365-$380 million, including $70-75 million from Lima.
它预计调整后的息税折旧摊销前利润为3.65-3.8亿美元，其中包括来自利马的7000万至7500万美元。
Full-year 2024 adjusted earnings per diluted share are expected to be $2.50-$2.65 versus consensus of $2.71.
2024年全年调整后的摊薄后每股收益预计为2.50美元至2.65美元，而市场预期为2.71美元。
William Blair says the integration of Lima has introduced various components affecting profit and loss. Despite this, initial analysis of the fourth-quarter results and 2024 guidance indicates that the expectation for sustained growth and enhanced margins is still valid.
威廉·布莱尔说，利马的一体化引入了影响盈亏的各种组成部分。尽管如此，对第四季度业绩和2024年指引的初步分析表明，对持续增长和利润率提高的预期仍然有效。
William Blair maintains an "Outperform" rating for the shares, considering their current valuation at 11 times the estimated EBITDA for 2025.
考虑到这些股票目前的估值是2025年预计息税折旧摊销前利润的11倍，威廉·布莱尔维持其股票的 “跑赢大盘” 评级。
Price Action: ENOV shares are up 7.56% at $64.83 on the last check Thursday.
价格走势：在周四的最后一次支票中，ENOV股价上涨7.56％，至64.83美元。